Applications for phase 3 of the Pathway Transformation Fund (PTF) are now open. The fund supports NHS organisations increase adoption of the 2020/21 Rapid Uptake Products RUPs, which are:

• Lipid Management: High Intensity Statins, Ezetimibe and PCSK9 inhibitors
• Measuring fractional exhaled nitric oxide (FeNO) concentration in asthma: products NIOX VERO and NObreath
• Biologics for treating severe asthma: Reslizumab, Benralizumab, Mepolizumab and Omalizumab

The PTF can help providers overcome practical obstacles to introducing these products, such as:

• Support set-up costs such as training and accreditation of staff;
• Pathway redesign and/or business support expertise;
• Providing funding for specialist nurses and clinical staff needed to implement a new part of the procedure; and
• Covering double running costs.

NHS organisations will be able to submit applications for PTF from 4 January 2021 until 12 noon, 30 April 2021. The application deadline has been extended from the original date of 11 February in recognition of the extreme challenges facing NHS organisations.

Applications should be developed and submitted with the support of your local AHSN RUP lead Aisha Ajij. This email address is being protected from spambots. You need JavaScript enabled to view it. for queries and further information.